Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2015

View Archived Issues

Sun Pharma announces collaboration to develop recombinant enzyme for stroke and glioblastoma

AstraZeneca and Wallenberg Centre for Protein Research collaborate to study secretome

Andes Biotechnologies begins first-in-human study evaluating Andes-1537

Anti-GDF8 MAb demonstrates efficacy in the treatment of sarcopenia

ImmBio begins first-in-human studies of PnuBioVax

Biogen begins phase I/II study of ISIS-SOD1-Rx in patients with ALS

Adocia and Lilly report phase I results for BioChaperone Lispro U200

Enrollment open in phase II/III study of TC BioPharm's ImmuniCell

Kyras Therapeutics launched to develop Ras family inhibitors for cancer

NeuroQuest extends validation trials of Alzheimer's disease blood test

Compound based on steroid hormone 20-hydroxyecdysone may improve sarcopenic obesity

FDA grants orphan drug designation to cromolyn sodium (inhaled) for mastocytosis

Atara Biotherapeutics reports data from proof-of-concept trial of PINTA-745

MAT-2501 granted QIDP designation by the FDA

Flindokalner given FDA orphan drug designation for Fragile X Syndrome

Horizon Pharma to acquire Crealta

Tuning T cell affinity improves bispecific antibody efficacy

New SARM has good safety and efficacy profile in monkeys

GlaxoSmithKline discloses ROR-gamma modulators

Cardioxyl Pharmaceuticals and Johns Hopkins University patent nitroxyl donors

Idenix Pharmaceuticals announces anticancer nucleoside derivatives

Sage Therapeutics presents GABA-A receptor modulators

CiRA and Takeda partner to develop clinical applications of induced pluripotent stem cells

Rebiotix starts clinical trial of RBX-2600 in children with ulcerative colitis

Akebia Therapeutics and Mitsubishi Tanabe Pharma sign agreement for vadadustat in Asia

Potassium channel modulator AUT-00206 affects negative symptoms in schizophrenia model

DMX-200 drug combination given FDA orphan designation for focal segmental glomerulosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...